



# MESCO PHARMACEUTICALS LTD

CIN : L24111UR1986PLC015895

REGD.OFFICE : UPPER KESALTON, TALLITAL, NAINITAL-263 001, UTTARAKHAND

Tel. :+91-9871862796, W: www.mesopharma.com; E-mail : nsparameswaran@mescosteel.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2017

(In Rs.)

SI No	PARTICULARS	Quarter Ended			Half Year ended		Year Ended
		30.09.2017	30.06.2017	30.09.2016	30.09.2017	30.09.2016	31.03.2017
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	<b>Income from Operations</b>						
	(a) Net Sales/ Income from operations	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Other Income	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Total Income from Operations (net)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
2	<b>Expenses</b>						
	(a) Cost of Material Consumed	0.00	0.00	0.00		0.00	0.00
	(b) Change in Inventories of finished goods and work in progress	0.00	0.00	0.00		0.00	0.00
	(c) Employees Benefits Expenses	75,000.00	81,387.00	73,597.00	156,387.00	141,565.00	374,505.00
	(d) Depreciation and Amortisation expenses	0.00	0.00	0.00	0.00	0.00	0.00
	(e) Finance Cost	0.00	0.00	0.00	0.00	0.00	0.00
	(f) Other Expenses	51,439.00	429,118.20	5,000.00	480,557.00	12,000.00	2,205,464.00
	<b>Total Expenses</b>	<b>126,439.00</b>	<b>510,505.20</b>	<b>78,597.00</b>	<b>636,944.00</b>	<b>153,565.00</b>	<b>2,579,969.00</b>
3	<b>Profit/(Loss) Before Exceptional items and Tax Finance Costs &amp; Exceptional Items (1-2)</b>	<b>(126,439.00)</b>	<b>(510,505.20)</b>	<b>(78,597.00)</b>	<b>(636,944.00)</b>	<b>(153,565.00)</b>	<b>(2,579,969.00)</b>
	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
4	<b>Profit/(Loss) before Tax</b>	<b>(126,439.00)</b>	<b>(510,505.20)</b>	<b>(78,597.00)</b>	<b>(636,944.00)</b>	<b>(153,565.00)</b>	<b>(2,579,969.00)</b>
	(a) Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Tax expense relating to Earlier years	0.00	0.00	0.00	0.00	0.00	9705.00
7	<b>Profit for the Period</b>	<b>(126,439.00)</b>	<b>(510,505.20)</b>	<b>(78,597.00)</b>	<b>(636,944.00)</b>	<b>(153,565.00)</b>	<b>(2,589,674.00)</b>
	<b>Other Comprehensive Income</b>						
	If any	-	-	-	-	-	-
	<b>Total Comprehensive Income for the Period</b>	<b>(126,439.00)</b>	<b>(510,505.20)</b>	<b>(78,597.00)</b>	<b>(636,944.00)</b>	<b>(153,565.00)</b>	<b>(2,589,674.00)</b>
14	Paid up Equity Share Capital (Face value Rs.10/- per Equity Share )	197,381,000.00	197,381,000.00	197,381,000.00	197,381,000.00	197,381,000.00	197,381,000.00
16	<b>Earning per share (before and after extraordinary items) (Rs.10- each)</b>						
	Basic (Rs.)	-(0.01)	(0.03)	(0.00)	(0.03)	(0.01)	(0.13)
	Diluted (Rs.)	(0.01)	(0.03)	(0.00)	(0.03)	(0.01)	(0.13)

**Notes :**

- The above Results, have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective Board Meeting held on 14th November, 2017
- The Statutory Auditors of the Company have carried out Limited Review of the above Results.
- Figures for the previous period have been re-classified, re-grouped/ re-arranged wherever necessary.
- There were no manufacturing activities in the company during the period under consideration

- 5 The Company has adopted Indian Accounting Standards ("Ind AS") from April 1, 2017 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder. Reconciliation of Net Profit / (Loss) from previous GAAP to Ind AS is as follows:

Particulars	Quarter Ended September 30,	Quarter Ended September 30,	Year ended March 31, 2017
<b>Net Profit/(Loss) as per Indian GAAP</b>	<b>(126,439.00)</b>	<b>(78,597.00)</b>	<b>(2,589,674.00)</b>
<b>Adjustments on account of:</b>			
Employees benefits	0.00	0.00	0.00
Leases	0.00	0.00	0.00
Others	0.00	0.00	0.00
<b>Total Comprehensive income as per Ind AS</b>	<b>(126,439.00)</b>	<b>(78,597.00)</b>	<b>(2,589,674.00)</b>

PLACE NEW DELHI  
DATED : 14.11.2017

*N.S. Parameswaran*  
N.S. PARAMESWARAN  
MANAGING DIRECTOR  
DIN : 00091097



## MESCO PHARMACEUTICALS LTD

CIN : L24111UR1986PLC015895

REGD.OFFICE : UPPER KESALTON, TALLITAL, NAINITAL-263 001, UTTARAKHAND

Tel. : +91-9871862796, W: www.mesopharma.com; E-mail : nsparameswaran@mescosteel.com

STATEMENT OF ASSETS AND LIABILITIES FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2017

(In Rs. )

	As at 30.09.2017 (Unaudited)	As at 31.03.2017 (audited)
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	1,798,761.00	1,798,761.00
Capital work-in-progress	-	-
Investment Property	-	-
<b>Non-current investments</b>	285,000.00	285,000.00
Financial assets :	-	-
Security deposit	-	-
Other financial assets	-	-
Other Non Current Assets	-	-
<b>Current assets</b>		
Inventories	-	-
Financial assets :		
Trade receivables	-	-
Cash and cash equivalents	395,918.00	394,768.00
Loans	-	-
Other financial assets	-	-
Prepayments	-	-
<b>Total Assets</b>	<b>2,479,679.00</b>	<b>2,478,529.00</b>
<b>EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
(a) Equity Share capital	197,381,000.00	197,381,000.00
(b) Other Equity	-	-
Equity Component of convertible Pref shares	-	-
Securities Premium	378,347,000.00	378,347,000.00
Treasury Shares	-	-
Retained Earnings	(891,959,481.00)	(891,322,536.00)
Reserve representing unrealised gains/losses	-	-
Foreign currency translation reserve	-	-
General Reserve	211,417,034.00	211,417,034.00
<b>Total Equity</b>	<b>(104,814,447.00)</b>	<b>(104,177,502.00)</b>
<b>Non-current liabilities</b>		
Financial liabilities:		
Borrowings	107,234,494.00	106,579,936.00
Trade Payables	-	-
Other Financial Liability	-	-
Deferred tax liabilities (net)	-	-
Employee Benefit Obligation	-	-
<b>Current liabilities</b>		
Financial liabilities:		
Trade payables	59,632.00	73,595.00
Other Financial Liability	-	-
Other payables	-	2,500.00
Employee Benefit Obligation	-	-
<b>Total Equity and Liabilities</b>	<b>2,479,679.00</b>	<b>2,478,529.00</b>

PLACE : NEW DELHI  
DATED : 14.11.2017

FOR AND ON BEHALF OF  
THE BOARD

N.S. PARAMESWARAN  
MANAGING DIRECTOR  
DIN : 00091097



# Sangram Paul & Co.

Chartered Accountants

Plot No.754/15, Jayadev Vihar, Bhubaneswar-751 013  
Phone: 0674-2360863 Mob.: 9337116878

**S.K.Paul. F.C.A**  
Chartered Accountant

## Review Report to MESCO PHARMACEUTICALS LIMITED


We have reviewed the accompanying statement of Unaudited financial results of **MESCO PHARMACEUTICALS LIMITED** for the quarter and half year ended September 30, 2017, being submitted by the company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, read with SEBI circular CIR/CFD/FAC/62/2016 dated July 5, 2016.


This statement is the responsibility of the Company's Management and approved by the Board of Directors has been prepared in accordance with Indian Accounting Standard ("IND-AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles general accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No: CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Sangram Paul & Co.**  
**Chartered Accountants**  
**Firm Registration No. 308001E**

  
**S.K. Paul**  
**Proprietor**  
**M. No.: - 013015**



**Date: 14<sup>th</sup> November, 2017**  
**Place: New Delhi**